Crocetin, a carotenoid compound found in saffron (Crocus sativus), has been studied for its neuroprotective and antioxidant properties, which have prompted investigation into its potential utility in stroke support and treatment. Preclinical studies, primarily in animal models, have shown that crocetin can reduce brain infarct size, decrease markers of oxidative stress, and mitigate neuronal damage following ischemic stroke. These effects are thought to arise from crocetin’s ability to scavenge free radicals, modulate inflammatory pathways, and improve mitochondrial function. For example, a 2019 study in rats demonstrated that crocetin administration after induced ischemia reduced neurological deficits and apoptosis in brain tissue.

However, the evidence supporting crocetin's use in human stroke patients remains limited. There are no large-scale, high-quality clinical trials evaluating its efficacy or safety in this context. Most available data come from in vitro experiments or animal studies, which do not always translate to clinical benefit in humans. As such, while there is a scientific rationale and some early preclinical validation for crocetin’s neuroprotective effects, the overall strength of evidence remains low (rated 2 out of 5). Further research, particularly well-designed human trials, is needed before crocetin can be recommended as a supportive or therapeutic agent for stroke.